Other languages Veru Inc.

Equities

VERU

US92536C1036

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
1.63 ^USD	-0.61%		+28.35%	+126.39%

Apr. 30	Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	CI
Apr. 15	Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	Apr. 30
Veru Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Apr. 01
Veru Inc. Appoints Louis Aronne as Chief Medical Advisor and A Member of the Scientific Advisory Board	Mar. 12
Veru Inc. Announces New Scientific Advisory Board for Its Enobosarm Program for High Quality Weight Loss	Feb. 20
Veru Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application for its Phase 2b Clinical Study	Feb. 06
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with Glp-1 Drugs for Weight Loss	Jan. 08
Veru Prices $33 Million Offering; Shares Fall	Dec. 14
Veru Launching Public Offering of Shares	Dec. 13
Veru Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 08
Veru Inc. Reports Muscle Data from 5 Clinical Studies of Enobosarm	23-10-04
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication	23-09-26
Veru Inc. Announces Clinical Data from Its Discontinued Phase 3 ARTEST Clinical Trial of Enobosarm Monotherapy	23-09-11
Veru Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-10
Veru Announces Executive Appointments	23-06-01
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-11
Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS	23-05-04
Veru Sells Entadfi Business for $20 Million Plus Up to $80 Million From Sales Milestones; Shares Up Pre-Bell	23-04-20
Veru Sets Accord With Afaxys to Offer FC2 Female Condom in US Public Health Centers	23-04-19
Veru Says Preclinical Data Show Sabizabulin Inhibits Poxviruses; Shares Rise	23-04-11
Veru Says Influenza Drug Candidate Showed 'Robust' Anti-Inflammatory Activity in Animal Study	23-04-04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Veru Inc.

Equities

VERU

US92536C1036

Other languages

Filters